prikaz prve stranice dokumenta Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
  Preuzmi
PDF 922 KB
Znanstveni rad - Izvorni znanstveni rad
Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
Haematologica, 104 (2019), 6; 1168-1175. https://doi.org/10.3324/haematol.2018.204826
Baron, Frédéric; Stevens-Kroef, Marian; Kicinski, Michal; Meloni, Giovanna; Muus, Petra; Marie, Jean-Pierre; Halkes, Constantijn J.M.; Thomas, Xavier; Vrhovac, Radovan; Albano, Francesco; Lefrère, François; Sica, Simona; Mancini, Marco; Venditti, Adriano; Hagemeijer, Anne; Jansen, Joop H.; Amadori, Sergio; de Witte, Theo; Willemze, Roelof; Suciu, Stefan Više autora...

Citirajte ovaj rad

Baron, F., Stevens Kroef, M., Kicinski, M., Meloni, G., Muus, P., Marie, J. P. ... Suciu, S. (2019). Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica, 104. (6), 1168-1175. doi: 10.3324/haematol.2018.204826

Baron, Frédéric, et al. "Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype." Haematologica, vol. 104, br. 6, 2019, str. 1168-1175. https://doi.org/10.3324/haematol.2018.204826

Baron, Frédéric, Marian Stevens Kroef, Michal Kicinski, Giovanna Meloni, Petra Muus, Jean Pierre Marie, Constantijn J.M. Halkes, et al. "Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype." Haematologica 104, br. 6 (2019): 1168-1175. https://doi.org/10.3324/haematol.2018.204826

Baron, F., et al. (2019) 'Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype', Haematologica, 104(6), str. 1168-1175. doi: 10.3324/haematol.2018.204826

Baron F, Stevens Kroef M, Kicinski M, Meloni G, Muus P, Marie JP, i sur.. Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. Haematologica [Internet]. 06.2019. [pristupljeno 09.11.2024.];104(6):1168-1175. doi: 10.3324/haematol.2018.204826

F. Baron, et al., "Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype", Haematologica, vol. 104, br. 6, str. 1168-1175, Lipanj 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:056120. [Citirano: 09.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:056120
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype
AutorFrédéric Baron
AutorMarian Stevens-Kroef
AutorMichal Kicinski
AutorGiovanna Meloni
AutorPetra Muus
AutorJean-Pierre Marie
AutorConstantijn J.M. Halkes
AutorXavier Thomas
AutorRadovan Vrhovac
AutorFrancesco Albano
AutorFrançois Lefrère
AutorSimona Sica
AutorMarco Mancini
AutorAdriano Venditti
AutorAnne Hagemeijer
AutorJoop H. Jansen
AutorSergio Amadori
AutorTheo de Witte
AutorRoelof Willemze
AutorStefan Suciu
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Monosomal karyotype confers a poor prognosis in patients with acute myeloid leukemia. Here, we determined the impact of the type of remission-induction chemotherapy and the impact of having a donor in younger acute myeloid leukemia patients with a monosomal karyotype included in two phase III trials. In the first trial patients were randomized to receive either daunorubicin, mitoxantrone, or idarubicin in addition to standard-dose cytarabine and etoposide for induction chemotherapy. In the second trial patients were randomized to standard-dose cytarabine or high-dose cytarabine induction, both with daunorubicin and etoposide. In both trials, patients who achieved a complete remission with or without complete hematologic recovery underwent allogeneic hematopoietic stem cell transplantation if they had a donor; otherwise, they underwent autologous transplantation. In comparison to patients with intermediate-risk cytogenetics without a monosomal karyotype (n=1,584) and with adverse cytogenetics without a monosomal karyotype (n=218), patients with a monosomal karyotype (n=188) were more likely not to achieve a complete remission with or without count recovery [odds ratio=2.85, 95% confidence interval (95%, CI): 2.10-3.88] and had shorter overall survival [hazard ratio, (HR)=2.44, 95% CI: 2.08-2.88]. There was no impact of the type of anthracycline or of the dose of cytarabine on outcomes in patients with a monosomal karyotype. Among monosomal karyo type patients who achieved a complete remission with or without count recovery, HLA-identical related donor availability was associated with longer survival from complete remission with or without count recovery (HR=0.59, 95% CI: 0.37-0.95). ClinicalTrials.gov identifiers: AML-10: NCT00002549; AML-12: NCT00004128.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHaematologica
Brojčani podacivol. 104, br. 6, str. 1168-1175
p-ISSN0390-6078
DOIhttps://doi.org/10.3324/haematol.2018.204826
URN:NBNurn:nbn:hr:105:056120
Datum objave publikacije2019-06
URL dokumentahttp://doi.org/10.3324/haematol.2018.204826
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 09:59:25